Losing the opportunity to study influenza drugs

JAMA

Volumn 303, Issue 9, 2010, Pages 878-879

  Meyerhoff, Andrea ^a,b   Lietman, Paul ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GexGroup Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

CLINICAL TRIAL; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; NOTE; PRIORITY JOURNAL;

EID: 77649206640     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.234     Document Type: Note

References (10)

1. Meyerhoff A, Lietman PS. All the world's a laboratory. New York Times. May 20, 2009:A23.
2. Tran TH, Ruiz-Palacios GM, Hayden FG, Farrar J. Patient-oriented pandemic influenza research. Lancet. 2009;373(9681):2085-2086.
3. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med. 2009;361(23):2204-2207.
4. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009;339:b5106.
5. BioCryst Pharmaceuticals. BioCryst receives peramivir request for proposal from the U.S. government [press release]. September 21, 2009. BioCryst receives first peramivir order from U.S. government [press release]. November 5, 2009. http: //investor.shareholder.com/biocryst/latestnews.cfm. Accessed December 9, 2009.
6. ClinicalTrials.gov database for peramivir studies. http://www. clinicaltrials.gov /ct2/results?term=peramivir. Accessed December 9, 2009.
7. Project Bioshield Act of 2004. Section 4: facilitating the use of medical countermeasures in an emergency. http://frwebgate.access.gpo.gov/cgi-bin/getdoc .cgi?dbname=108-cong-public-laws&docid=f:publ276.108.pdf. Accessed February 5, 2010.
8. FDA. Emergency Use Authorization of peramivir IV: fact sheet for health care providers. http://www.fda.gov/downloads/Drugs/DrugSafety /PostmarketDrugSafety/Information for patients and providers/UCM187811 .pdf. Posted November 19, 2009. Accessed January 5, 2010.
9. FDA. FDA approved label and Medical Officer Reviews for Tamiflu (oseltamivir) and Relenza (zanamivir). http://www.accessdata.fda.gov/scripts/ cder/drugsatfda /index.cfm?CFID=31296985&CFTOKEN=8b5d553a66731dd9-487E07E2 -1143-D1C5-FBB1921CF5C6B926 and http://www.accessdata.fda.gov/scripts /cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed January 6, 2010.
10. Department of Health and Human Services. Summary report of the National Biodefense Science Board (NBSB) public teleconference of November 13, 2009. http://www.hhs.gov/aspr/conferences/nbsb/nbsb-summary-111309.pdf. Accessed January 19, 2010.